Hubbry Logo
HivesHivesMain
Open search
Hives
Community hub
Hives
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Hives
Hives
from Wikipedia
Hives
Other namesUrticaria
Hives on the arm
SpecialtyDermatology, Clinical immunology, Allergology
SymptomsRed, raised, itchy bumps[1]
DurationA few days[1]
CausesStress, following an infection, result of an allergic reaction[2]
Risk factorsHay fever, asthma[3]
Diagnostic methodBased on symptoms, patch testing[2]
TreatmentAntihistamines, corticosteroids, leukotriene inhibitors[2]
Frequency~20%[2]

Hives, also known as urticaria, is a kind of skin rash with red or flesh-colored, raised, itchy bumps.[1] Hives may burn or sting.[2] The patches of rash may appear on different body parts,[2] with variable duration from minutes to days, and typically do not leave any long-lasting skin change.[2] Fewer than 5% of cases last for more than six weeks (a condition known as chronic urticaria).[2] The condition frequently recurs.[2][4]

Hives frequently occur following an infection or as a result of an allergic reaction such as to medication, insect bites, or food.[2] Psychological stress, cold temperature, or vibration may also be a trigger.[1][2] In half of cases the cause remains unknown.[2] Risk factors include having conditions such as hay fever or asthma.[3] Diagnosis is typically based on appearance.[2] Patch testing may be useful to determine the allergy.[2]

Prevention is by avoiding whatever it is that causes the condition.[2] Treatment is typically with antihistamines, with the second generation antihistamines such as fexofenadine, loratadine and cetirizine being preferred due to less risk of sedation and cognitive impairment.[4] In refractory (obstinate) cases, corticosteroids or leukotriene inhibitors may also be used.[2] Keeping the environmental temperature cool is also useful.[2] For cases that last more than six weeks, long-term antihistamine therapy is indicated. Immunosuppressants such as omalizumab or cyclosporin may also be used.[4]

About 20% of people are affected at some point in their lives.[2] Short duration cases occur equally in males and females, lasting a few days and without leaving any long-lasting skin changes.[2] Long duration cases are more common in females.[5] Short duration cases are also more common among children, while long duration cases are more common among those who are middle-aged.[5] Hives have been described since at least the time of Hippocrates.[5] The term urticaria is from the Latin urtica meaning "nettle".[6]

Signs and symptoms

[edit]
Hives on the left chest wall. They are slightly raised.
Hives
Drawing of hives

Hives, or urticaria, is a form of skin rash with red, raised, itchy bumps.[1] They may also burn or sting.[2] Hives can appear anywhere on the surface of the skin. Whether the trigger is allergic or not, a complex release of inflammatory mediators, including histamine from cutaneous mast cells, results in fluid leakage from superficial blood vessels. Hives may be pinpoint in size or several inches in diameter, they can be individual or confluent, coalescing into larger forms.[4]

Angioedema is a related condition (also from allergic and nonallergic causes), though fluid leakage is from much deeper blood vessels in the subcutaneous or submucosal layers. Individual hives that are painful, last more than 24 hours, or leave a bruise as they heal are more likely to be a more serious condition called urticarial vasculitis. Hives caused by stroking the skin (often linear in appearance) are due to a benign condition called dermatographic urticaria.[citation needed]

Cause

[edit]

Hives can also be classified by the purported causative agent. Many different substances in the environment may cause hives, including medications, food and physical agents. In perhaps more than 50% of people with chronic hives of unknown cause, it is due to an autoimmune reaction.[7] Risk factors include having conditions such as hay fever or asthma.[3]

Medications

[edit]

Drugs that have caused allergic reactions evidenced as hives include codeine, sulphate of morphia, dextroamphetamine,[8] aspirin, ibuprofen, penicillin, clotrimazole, trichazole, sulfonamides, anticonvulsants, cefaclor, piracetam, vaccines, and antidiabetic drugs. The antidiabetic sulphonylurea glimepiride, in particular, has been documented to induce allergic reactions manifesting as hives.[citation needed]

Food

[edit]

The most common food allergies in adults are shellfish and nuts. The most common food allergies in children are shellfish, nuts, eggs, wheat, and soy. One study showed Balsam of Peru, which is in many processed foods, to be the most common cause of immediate contact urticaria.[9] Another food allergy that can cause hives is alpha-gal allergy, which may cause sensitivity to milk and red meat. A less common cause is exposure to certain bacteria, such as Streptococcus species or possibly Helicobacter pylori.[10]

Infection or environmental agent

[edit]

Hives including chronic spontaneous hives can be a complication and symptom of a parasitic infection, such as blastocystosis and strongyloidiasis among others.[11]

The rash that develops from poison ivy, poison oak, and poison sumac contact is commonly mistaken for urticaria. This rash is caused by contact with urushiol and results in a form of contact dermatitis called urushiol-induced contact dermatitis. Urushiol is spread by contact but can be washed off with a strong grease- or oil-dissolving detergent and cool water and rubbing ointments.[citation needed]

Dermatographic urticaria

[edit]

Dermatographic urticaria (also known as dermatographism or "skin writing") is marked by the appearance of weals or welts on the skin as a result of scratching or firm stroking of the skin. Seen in 4–5% of the population, it is one of the most common types of urticaria,[12] in which the skin becomes raised and inflamed when stroked, scratched, rubbed, and sometimes even slapped.[13]

The skin reaction usually becomes evident soon after the scratching and disappears within 30 minutes. Dermatographism is the most common form of a subset of chronic hives, acknowledged as "physical hives".[citation needed]

It stands in contrast to the linear reddening that does not itch seen in healthy people who are scratched. In most cases, the cause is unknown, although it may be preceded by a viral infection, antibiotic therapy, or emotional upset. Dermatographism is diagnosed by applying pressure by stroking or scratching the skin.[14] The hives should develop within a few minutes. Unless the skin is highly sensitive and reacts continually, treatment is not needed. Taking antihistamines can reduce the response in cases that are annoying to the person.[citation needed]

Pressure or delayed pressure

[edit]

This type of hives can occur right away, precisely after a pressure stimulus or as a deferred response to sustained pressure being enforced to the skin. In the deferred form, the hives only appear after about six hours from the initial application of pressure to the skin. Under normal circumstances, these hives are not the same as those witnessed with most urticariae. Instead, the protrusion in the affected areas is typically more spread out. The hives may last from eight hours to three days. The source of the pressure on the skin can happen from tight fitted clothing, belts, clothing with tough straps, walking, leaning against an object, standing, sitting on a hard surface, etc. The areas of the body most commonly affected are the hands, feet, trunk, abdomen, buttocks, legs and face. Although this appears to be very similar to dermatographism, the cardinal difference is that the swelled skin areas do not become visible quickly and tend to last much longer. This form of the skin disease is, however, rare.[citation needed]

Cholinergic or stress

[edit]

Cholinergic urticaria (CU) is one of the physical urticaria which is provoked during sweating events such as exercise, bathing, staying in a heated environment, or emotional stress. The hives produced are typically smaller than classic hives and are generally shorter-lasting.[15][16]

Multiple subtypes have been elucidated, each of which require distinct treatment.[17][18]

Cold-induced

[edit]

The cold type of urticaria is caused by exposure of the skin to extreme cold, damp and windy conditions; it occurs in two forms. The rare form is hereditary and becomes evident as hives all over the body 9 to 18 hours after cold exposure. The common form of cold urticaria demonstrates itself with the rapid onset of hives on the face, neck, or hands after exposure to cold. Cold urticaria is common and lasts for an average of five to six years. The population most affected is young adults, between 18 and 25 years old. Many people with the condition also have dermographism and cholinergic hives.[citation needed]

Severe reactions can be seen with exposure to cold water; swimming in cold water is the most common cause of a severe reaction. This can cause a massive discharge of histamine, resulting in low blood pressure, fainting, shock and even loss of life. Cold urticaria is diagnosed by dabbing an ice cube against the skin of the forearm for 1 to 5 minutes. A distinct hive should develop if a person has cold urticaria. This is different from the normal redness that can be seen in people without cold urticaria. People with cold urticaria need to learn to protect themselves from a hasty drop in body temperature. Regular antihistamines are not generally efficacious. One particular antihistamine, cyproheptadine (Periactin), has been found to be useful. The tricyclic antidepressant doxepin has been found to be effective blocking agents of histamine. Finally, a medication named ketotifen, which keeps mast cells from discharging histamine, has also been employed with widespread success.[citation needed]

Solar urticaria

[edit]

This form of the disease occurs on areas of the skin exposed to the sun; the condition becomes evident within minutes of exposure.[citation needed]

Water-induced

[edit]

This type of urticaria is also termed rare and occurs upon contact with water. The response is not temperature-dependent and the skin appears similar to the cholinergic form of the disease. The appearance of hives is within one to 15 minutes of contact with the water and can last from 10 minutes to two hours. This kind of hives does not seem to be stimulated by histamine discharge like the other physical hives. Most researchers believe this condition is actually skin sensitivity to additives in the water, such as chlorine. Water urticaria is diagnosed by dabbing tap water and distilled water to the skin and observing the gradual response. Aquagenic urticaria is treated with capsaicin (Zostrix) administered to the chafed skin. This is the same treatment used for shingles. Antihistamines are of questionable benefit in this instance since histamine is not the causative factor.[citation needed]

Exercise

[edit]

The condition was first distinguished in 1980. People with exercise urticaria (EU) experience hives, itchiness, shortness of breath and low blood pressure five to 30 minutes after beginning exercise. These symptoms can progress to shock and even sudden death. Jogging is the most common exercise to cause EU, but it is not induced by a hot shower, fever, or with fretfulness. This differentiates EU from cholinergic urticaria.[citation needed]

EU sometimes occurs only when someone exercises within 30 minutes of eating particular foods, such as wheat or shellfish. For these individuals, exercising alone or eating the injuring food without exercising produces no symptoms. EU can be diagnosed by having the person exercise and then observing the symptoms. This method must be used with caution and only with the appropriate resuscitative measures at hand. EU can be differentiated from cholinergic urticaria by the hot water immersion test. In this test, the person is immersed in water at 43 °C (109.4 °F). Someone with EU will not develop hives, while a person with cholinergic urticaria will develop the characteristic small hives, especially on the neck and chest.[citation needed]

The immediate symptoms of this type are treated with antihistamines, epinephrine and airway support. Taking antihistamines prior to exercise may be effective. Ketotifen is acknowledged to stabilise mast cells and prevent histamine release, and has been effective in treating this hives disorder. Avoiding exercise or foods that cause the mentioned symptoms is very important. In particular circumstances, tolerance can be brought on by regular exercise, but this must be under medical supervision.[citation needed]

Pathophysiology

[edit]

The skin lesions of urticarial disease are caused by an inflammatory reaction in the skin, causing leakage of capillaries in the dermis, and resulting in an edema which persists until the interstitial fluid is absorbed into the surrounding cells.[citation needed]

Hives are caused by the release of histamine and other mediators of inflammation (cytokines) from cells in the skin. This process can be the result of an allergic or nonallergic reaction, differing in the eliciting mechanism of histamine release.[19]

Allergic hives

[edit]

Histamine and other proinflammatory substances are released from mast cells in the skin and tissues in response to the binding of allergen-bound IgE antibodies to high-affinity cell surface receptors. Basophils and other inflammatory cells are also seen to release histamine and other mediators, and are thought to play an important role, especially in chronic urticarial diseases.[citation needed]

Autoimmune hives

[edit]

Over half of all cases of chronic idiopathic hives are the result of an autoimmune trigger. Roughly 50% of people with chronic urticaria spontaneously develop autoantibodies directed at the receptor FcεRI located on skin mast cells. Chronic stimulation of this receptor leads to chronic hives. People with hives often have other autoimmune conditions, such as autoimmune thyroiditis, celiac disease, type 1 diabetes, rheumatoid arthritis, Sjögren's syndrome or systemic lupus erythematosus.[7]

Infections

[edit]

Hive-like rashes commonly accompany viral illnesses, such as the common cold. They usually appear three to five days after the cold has started, and may even appear a few days after the cold has resolved.[citation needed]

Nonallergic hives

[edit]

Mechanisms other than allergen-antibody interactions are known to cause histamine release from mast cells. Many drugs, for example morphine, can induce direct histamine release not involving any immunoglobulin molecule. Also, a diverse group of signaling substances called neuropeptides, have been found to be involved in emotionally induced hives. Dominantly inherited cutaneous and neurocutaneous porphyrias (porphyria cutanea tarda, hereditary coproporphyria, variegate porphyria and erythropoietic protoporphyria) have been associated with solar urticaria. The occurrence of drug-induced solar urticaria may be associated with porphyrias. This may be caused by IgG binding, not IgE.[citation needed]

Dietary histamine poisoning

[edit]

This is termed scombroid food poisoning. Ingestion of free histamine released by bacterial decay in fish flesh may result in a rapid-onset, allergic-type symptom complex which includes hives. However, the hives produced by scombroid is reported not to include wheals.[20]

Stress and chronic idiopathic hives

[edit]

Chronic idiopathic hives has been anecdotally linked to stress since the 1940s.[21] A large body of evidence demonstrates an association between this condition and both poor emotional well-being[22] and reduced health-related quality of life.[23] A link between stress and this condition has also been shown.[24] Some cases have been thought to be due to stress, including an association between post-traumatic stress and chronic idiopathic hives.[25][26] In most cases of chronic idiopathic urticaria, no cause is identified.[4]

Diagnosis

[edit]
Micrograph of urticaria. Dermal edema [solid arrows in (A, B)] and a sparse superficial predominantly perivascular and interstitial infiltrate of lymphocytes and eosinophils without signs of vasculitis (dashed arrow).[27]

Diagnosis is typically based on the appearance.[2] The cause of chronic hives can rarely be determined.[28] Patch testing may be useful to determine the allergy.[2] In some cases regular extensive allergy testing over a long period of time is requested in hopes of getting new insight.[29][30] No evidence shows regular allergy testing results in identification of a problem or relief for people with chronic hives.[29][30] Regular allergy testing for people with chronic hives is not recommended.[28]

Acute versus chronic

[edit]
  • Acute urticaria is defined as the presence of evanescent wheals which completely resolve within six weeks.[31] Acute urticaria becomes evident a few minutes after the person has been exposed to an allergen. The outbreak may last several weeks, but usually the hives are gone in six weeks. Typically, the hives are a reaction to food, but in about half the cases, the trigger is unknown. Common foods may be the cause, as well as bee or wasp stings, or skin contact with certain fragrances. Acute viral infection is another common cause of acute urticaria (viral exanthem). Less common causes of hives include friction, pressure, temperature extremes, exercise, and sunlight.[citation needed]
  • Chronic urticaria is defined as the presence of hives which persist for greater than six weeks.[31] Some of the more severe chronic cases have lasted more than 20 years. A survey indicated chronic urticaria lasted a year or more in more than 50% of those affected and 20 years or more in 20% of them.[32] Provocative skin challenge testing may be done in those with chronic urticaria, in which the skin is exposed to pressure (dermatographisim), cold temperatures, warm temperatures, or light in an attempt to provoke symptoms and aid in the diagnosis.[4] The history of physical examination guide the diagnosis of chronic urticaria, with extensive lab testing not recommended.[4][33]

Acute and chronic hives are visually indistinguishable on visual inspection alone.[citation needed]

[edit]

Angioedema

[edit]

Angioedema is similar to hives,[34] but in angioedema, the swelling occurs in a lower layer of the dermis than in hives,[35] as well as in the subcutis. This swelling can occur around the mouth, eyes, in the throat, in the abdomen, or in other locations. Hives and angioedema sometimes occur together in response to an allergen, and is a concern in severe cases, as angioedema of the throat can be fatal.[citation needed]

Vibratory angioedema

[edit]

This very rare form of angioedema develops in response to contact with vibration. In vibratory angioedema, symptoms develop within two to five minutes after contact with a vibrating object and abate after about an hour. People with this disorder do not experience dermographism or pressure urticaria. Vibratory angioedema is diagnosed by holding a vibrating device such as a laboratory vortex machine against the forearm for four minutes. Speedy swelling of the whole forearm extending into the upper arm is also noted later. The principal treatment is avoidance of vibratory stimulants. Antihistamines have also been proven helpful.[citation needed]

Management

[edit]

The mainstay of therapy for both acute and chronic hives is education, avoiding triggers and using antihistamines.[citation needed]

Chronic hives can be difficult to treat and lead to significant disability. Unlike the acute form, 50–80% of people with chronic hives have no identifiable triggers. But 50% of people with chronic hives will experience remission within 1 year.[36] Overall, treatment is geared towards symptomatic management. Individuals with chronic hives may need other medications in addition to antihistamines to control symptoms. People who experience hives with angioedema require emergency treatment as this is a life-threatening condition.[citation needed]

Treatment guidelines for the management of chronic hives have been published.[37][38] According to the 2014 American practice parameters, treatment involves a stepwise approach. Step 1 consists of second generation, H1 receptor blocking antihistamines. Systemic glucocorticoids can also be used for episodes of severe disease but should not be used for long term due to their long list of side effects. Step 2 consists of increasing the dose of the current antihistamine, adding other antihistamines, or adding a leukotriene receptor antagonist such as montelukast. Step 3 consists of adding or replacing the current treatment with hydroxyzine or doxepin. If the individual doesn't respond to steps 1–3 then they are considered to have refractory symptoms. At this point, anti-inflammatory medications (dapsone, sulfasalazine), immunosuppressants (cyclosporin, sirolimus) or other medications like omalizumab can be used. These options are explained in more detail below.[citation needed]

First generation antihistamines, such as diphenhydramine or hydroxyzine, are not recommended as a first line therapy as they block both brain and peripheral H1 receptors, causing sedation. Second-generation antihistamines, such as loratadine, cetirizine, fexofenadine or desloratadine, selectively antagonize peripheral H1 receptors, and are less sedating, less anticholinergic, and generally preferred over the first-generation antihistamines.[39][40] Fexofenadine, a new-generation antihistamine that blocks histamine H1 receptors, may be less sedating than some second-generation antihistamines.[41]

People who do not respond to the maximum dose of H1 antihistamines may benefit from increasing the dose further, then to switching to another non-sedating antihistamine, then to adding a leukotriene antagonist, then to using an older antihistamine, then to using systemic steroids and finally to using ciclosporin or omalizumab.[39] Steroids are often associated with rebound hives once discontinued.[4]

H2-receptor antagonists are sometimes used in addition to H1-antagonists to treat urticaria, but there is limited evidence for their efficacy.[42]

Systemic steroids

[edit]

Oral glucocorticoids are effective in controlling symptoms of chronic hives. However, they have an extensive list of adverse effects, such as adrenal suppression, weight gain, osteoporosis, hyperglycemia, etc. Therefore, their use should be limited to a couple of weeks. In addition, one study found that systemic glucocorticoids combined with antihistamines did not hasten the time to symptom control compared with antihistamines alone.[43]

Leukotriene-receptor antagonists

[edit]

Leukotrienes are released from mast cells along with histamine. The medications, montelukast and zafirlukast, inhibit leukotriene effects, and may be useful as add-on treatment or in isolation for people with CU.[44] A 2024 review found that montelukast and zafirlukast, when used in addition to H1 antihistamines, have a small effect in reducing urticaria with no significant adverse effects.[44]

Other

[edit]

Other options for refractory symptoms of chronic hives include anti-inflammatory medications, omalizumab, and immunosuppressants. Potential anti-inflammatory agents include dapsone, sulfasalazine, and hydroxychloroquine. Dapsone is a sulfone antimicrobial agent and is thought to suppress prostaglandin and leukotriene activity. It is helpful in therapy-refractory cases[45] and is contraindicated in people with G6PD deficiency. Sulfasalazine, a 5-ASA derivative, is thought to alter adenosine release and inhibit IgE mediated mast cell degranulation, Sulfasalazine is a good option for people with anemia who cannot take dapsone. Hydroxychloroquine is an antimalarial agent that suppresses T lymphocytes. It has a low cost however it takes longer than dapsone or sulfasalazine to work.[citation needed]

Omalizumab was approved by the FDA in 2014 for people with hives 12 years old and above with chronic hives. It is a monoclonal antibody directed against IgE. Significant improvement in pruritus and quality of life was observed in a phase III, multicenter, randomized control trial.[46]

Immunosuppressants used for CU include cyclosporine, tacrolimus, sirolimus, and mycophenolate. Calcineurin inhibitors, such as cyclosporine and tacrolimus, inhibit cell responsiveness to mast cell products and inhibit T cell activity. They are preferred by some experts to treat severe symptoms.[47] Sirolimus and mycophenolate have less evidence for their use in the treatment of chronic hives but reports have shown them to be efficacious.[48][49] Immunosuppressants are generally reserved as the last line of therapy for severe cases due to their potential for serious adverse effects.[citation needed]

A 2025 systematic review and network meta-analysis found that among patients with chronic hives that were inadequately controlled with antihistamines, omalizumab and remibrutinib were among the most effective, while cyclosporine may be among the most harmful.[50]

Prognosis

[edit]

In those with chronic urticaria, defined as either continuous or intermittent symptoms lasting longer than 6 weeks, 35% of people are symptom free 1 year after treatment, while 29% have a reduction in their symptoms.[4] Those with a longer disease duration typically have a worse prognosis, with greater symptom severity.[4] Chronic urticaria is often accompanied by an intense pruritus, and other symptoms associated with a reduced quality of life and a high burden of co-morbid psychiatric conditions such as anxiety and depression.[4][51] The prevalence of depressive symptoms, anxiety symptoms, and sleep disturbances in patients with chronic urticaria has been estimated to be 37%, 46%, and 53%, respectively.[52]

Epidemiology

[edit]

Chronic urticaria is usually seen in those older than 40 years, it is more common in women.[4] The prevalence of chronic urticaria is 0.23% in the United States.[4] Notable risk factors associated with an increased risk of chronic urticaria include allergic rhinitis, asthma, atopic dermatitis, and autoimmune thyroid disorders.[53]

Research

[edit]

Afamelanotide is being studied as a hives treatment.[54]

Opioid antagonists such as naltrexone have tentative evidence to support their use.[55]

History

[edit]

The term urticaria was first used by the Scottish physician William Cullen in 1769.[56] It originates from the Latin word urtica, meaning stinging hair or nettle,[6] as the classical presentation follows the contact with a perennial flowering plant Urtica dioica.[57] The history of urticaria dates back to 1000–2000 BC with its reference as a wind-type concealed rash in the book The Yellow Emperor's Inner Classic from Huangdi Neijing. Hippocrates in the 4th century first described urticaria as "knidosis" after the Greek word knido for nettle.[58] The discovery of mast cells by Paul Ehrlich in 1879 brought urticaria and similar conditions under a comprehensive idea of allergic conditions.[59]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Hives, also known as urticaria, are itchy, raised welts that appear suddenly on the skin, ranging in size from small spots to large patches and often resulting from allergic reactions or other triggers. These welts, which can be red, pink, or skin-colored, typically last less than 24 hours in any one area but may recur in different locations, and they affect approximately 25% of the population at some point in their lives. Hives are frequently accompanied by , a deeper swelling of the skin or mucous membranes that can occur in areas like the face, , or , potentially leading to more severe complications if it affects the airways. Urticaria is classified into acute and chronic forms based on duration: acute hives resolve within six weeks, while chronic hives persist beyond this period and affect about 1% of the population, often without an identifiable cause. Common causes of acute hives include allergic responses to foods such as or , medications like penicillin or aspirin, stings, viral infections, or environmental factors like . In chronic cases, triggers may involve autoimmune processes, physical stimuli such as pressure or cold, or remain idiopathic in up to 90% of instances. Risk factors include a personal or family history of allergies, , or previous episodes of hives, with women being more commonly affected than men in chronic forms. Symptoms of hives primarily involve intense itching, though some individuals experience burning or stinging sensations, and the welts may blanch under pressure, revealing a pale center surrounded by redness. adds painful or warm swelling that can last up to 72 hours, and in rare hereditary cases like (HAE), it stems from genetic deficiencies rather than allergies. typically relies on clinical and , with tests or blood work used to identify triggers when possible. Treatment focuses on symptom relief and trigger avoidance; first-line options include non-sedating antihistamines like or fexofenadine, which provide relief for about 50% of chronic cases. For refractory chronic urticaria, biologic therapies such as offer response rates of up to 65%, while short-term corticosteroids may be used for severe flares. Most acute episodes resolve spontaneously, and even chronic hives improve in 50% of patients within one to two years, with 80-90% achieving resolution by five years. Complications are uncommon but can include in allergic cases or life-threatening airway obstruction from . For chronic cases, triggers may involve autoimmune processes, physical stimuli such as pressure or cold, or remain idiopathic in up to 90% of instances.

Signs and Symptoms

Clinical Presentation

Sudden widespread itching (pruritus) and skin rash are most commonly caused by acute urticaria (hives), with the rash often appearing as raised, itchy welts that appear suddenly and can spread quickly. Hives, also known as urticaria, present as transient, raised lesions called wheals, which are typically erythematous (red) on lighter skin tones or skin-colored on darker tones, and vary in from a few millimeters to several centimeters in diameter. These wheals are well-circumscribed, edematous, and can appear round, irregular, annular, or in shape, often coalescing into larger plaques that may cover significant areas of the body. A hallmark feature is their blanching upon , where the central area temporarily turns white due to compression of dilated blood vessels, distinguishing them from other eruptions. The primary sensory symptom associated with hives is intense pruritus (itching), which is often severe enough to interfere with daily activities and sleep, accompanied in some cases by a burning or stinging sensation. In addition to superficial wheals, hives may involve deeper dermal or subcutaneous layers, leading to , which manifests as non-pitting swelling that feels warm and tender rather than itchy, commonly affecting the , eyelids, face, extremities, or genitalia. If hives or angioedema are accompanied by facial or throat swelling, difficulty breathing, or other signs of anaphylaxis, immediate emergency medical care should be sought. Hives are particularly common in infants and young children, where they typically appear as itchy, raised red welts or patches on the skin that vary in size and often fade within hours to days, sometimes with associated swelling. Small welts on a toddler's face are commonly caused by hives (urticaria), presenting as raised, red, itchy welts. Symptoms include itching or stinging sensations, and episodes in this age group are most frequently associated with minor viral infections, allergic reactions (such as to foods, medications, insect bites/stings, or cow's milk in recurrent cases), or unknown causes. In infants with allergic urticaria, the condition primarily manifests as itchy, red, raised welts on the skin, often accompanied by angioedema leading to swelling, puffiness, or blotchy redness around the eyes. While red eyes (conjunctival redness or pink appearance) are not a direct symptom of urticaria, they may occur if concurrent allergic conjunctivitis or a severe allergic reaction is present. Individual lesions characteristically appear suddenly and migrate across the skin, resolving within 1 to 24 hours without scarring, while new wheals emerge in different locations, creating a dynamic, evanescent pattern. Hives most frequently occur on the trunk, limbs, and face, though they can arise anywhere on the body surface, and approximately 15-25% of individuals experience at least one during their lifetime. This clinical presentation can differ in chronic forms, where symptoms persist beyond six weeks, but the acute features of wheals and remain similar.

Duration and Patterns

Hives, or urticaria, are classified temporally into acute and chronic forms based on the overall duration of symptoms. Acute urticaria is defined as episodes lasting less than 6 weeks, with individual wheals typically emerging over minutes to hours and resolving spontaneously within 24 hours, though the full episode often clears within hours to days. In contrast, chronic urticaria persists for more than 6 weeks and is subdivided into , which occurs without identifiable triggers and affects approximately 0.5-1% of the , and chronic inducible urticaria, which is elicited by specific physical or non-physical stimuli such as or changes. Patterns of urticaria manifestation vary, often involving daily or almost daily flares in chronic cases, with intermittent recurrences possible in up to 20-30% of acute episodes that may progress to chronicity, particularly in pediatric populations where infections play a role. Symptoms frequently worsen nocturnally, with nighttime reported as the most common period for clinical exacerbation, potentially due to heat from bedding or reduced environmental controls. Individual lesions in both acute and chronic urticaria resolve without scarring or residual , returning the skin to its normal state. The duration of chronic urticaria is variable, with up to 50% of cases lasting more than 1 year, though many achieve remission within 2-5 years; flares triggered by , such as during exercise or warm environments, can prolong discomfort in inducible subtypes. These temporal patterns underscore the self-limiting nature of most urticaria, distinguishing it from persistent dermatoses that leave marks.

Causes and Triggers

Allergic and Nonallergic Reactions

Allergic reactions causing hives, also known as urticaria, are primarily IgE-mediated type I hypersensitivity responses triggered by specific allergens, leading to rapid mast cell activation and wheal formation typically within minutes to hours of exposure. These reactions commonly result in acute urticaria, characterized by sudden widespread itching (pruritus) and a skin rash of raised, itchy welts that can spread quickly. Common food allergens include peanuts, tree nuts, shellfish, fish, milk, and eggs, which can provoke acute episodes upon ingestion. Medications such as penicillins, cephalosporins, and nonsteroidal anti-inflammatory drugs (NSAIDs) are frequent culprits in IgE-mediated urticaria, often manifesting as part of a broader hypersensitivity reaction. Insect stings from Hymenoptera species, like bees or wasps, can also initiate these reactions through venom-specific IgE antibodies, resulting in localized or generalized hives shortly after envenomation. Airborne allergens, such as pollen and pet dander, can trigger similar IgE-mediated urticaria in susceptible individuals. In babies and young children, hives are commonly caused by viral infections, often accompanied by symptoms of a cold or diarrhea, as well as by allergic reactions to foods such as cow's milk (particularly in cases of recurrence), insect stings, or unknown triggers. Recurrent hives in babies may indicate an allergy such as to cow's milk. Nonallergic reactions, often termed pseudoallergic, mimic allergic urticaria but occur without IgE involvement, instead involving direct or pharmacological effects that release and other mediators. Aspirin and other NSAIDs commonly provoke these responses by inhibiting enzymes, leading to altered metabolism and subsequent urticaria in susceptible individuals. Radiocontrast media used in imaging procedures can cause immediate pseudoallergic urticaria through direct liberation from s, affecting up to 1-3% of administrations. Opiates, such as , induce via opioid stimulation on s, producing hives independent of prior . These pseudoallergic mechanisms highlight how certain substances can bypass immune-specific pathways yet produce clinically indistinguishable symptoms. Among food-related triggers, histamine-rich foods such as aged cheeses (e.g., , ) and fermented products (e.g., , ) can exacerbate urticaria in individuals with , leading to symptoms resembling scombroid poisoning, including flushing, rash, and hives due to excessive intake overwhelming degradation pathways. Scombroid-like reactions from these foods typically onset within minutes to an hour, mimicking allergic responses without true . Medications are implicated in approximately 3-10% of acute urticaria cases, underscoring their role as a leading identifiable trigger in short-duration episodes. In contrast, true food allergies rarely underlie chronic urticaria, accounting for less than 2% of persistent cases, where triggers are more often idiopathic or multifactorial.

Physical and Inducible Factors

Physical and inducible factors refer to external stimuli that provoke hives, known as chronic inducible urticaria (CIndU), a subset of chronic urticaria characterized by recurrent wheals and sometimes elicited by specific physical or environmental triggers. These conditions differ from spontaneous urticaria by their predictable response to provocation, often manifesting as localized reactions that are typically chronic in nature, lasting more than . CIndU affects approximately 0.5% of the general and accounts for up to 25% of all chronic urticaria cases, with symptoms frequently confined to the site of stimulation. Dermatographic urticaria, also termed symptomatic dermographism, is the most prevalent form of CIndU, occurring in response to light stroking or friction on the skin, resulting in linear wheals that appear within minutes and are accompanied by itching. This mechanical trigger leads to transient erythematous lines or raised welts tracing the path of irritation, often without deeper tissue involvement, and it can be elicited in up to 68% of CIndU patients in clinical cohorts. The reaction is generally benign and self-limited, resolving within 30-60 minutes, though it may contribute to daily discomfort in affected individuals. Pressure urticaria involves hives triggered by sustained mechanical on the skin, such as from tight , belts, or prolonged standing, with two main variants: immediate and delayed. The delayed form, which is more common, develops 30 minutes to several hours after pressure application, presenting as painful, erythematous swellings that can persist for up to 48 hours and may involve deeper dermal layers, distinguishing it from superficial reactions. Examples include wheals under waistbands or on the soles after walking, highlighting its relevance to everyday activities. Cold urticaria is provoked by exposure to low temperatures, manifesting as hives upon contact with cold air, water, or objects, with wheals forming rapidly after rewarming; subtypes include acquired (true) cold contact urticaria and familial cold autoinflammatory syndrome, potentially risking systemic reactions like in severe cases. , a separate inducible form often linked to exercise, hot baths, or emotional stress, produces small, punctate wheals with burning sensations due to increased body temperature and sweating, affecting about 11% of CIndU patients. , another distinct variant, is elicited by any water contact irrespective of temperature, causing pruritic wheals within minutes that resolve quickly, as seen in responses to tap water immersion. Other inducible forms include , triggered by ultraviolet light exposure, leading to rapid-onset wheals on sun-exposed skin within minutes; vibratory urticaria, induced by prolonged friction or vibration such as from machinery or jogging, resulting in localized hives; and exercise-induced flares, which overlap with mechanisms and produce widespread itching during physical exertion. These subtypes underscore the diverse environmental sensitivities in CIndU, often coexisting in the same patient and contributing to its chronic, localized pattern.

Underlying Medical Conditions

Underlying medical conditions can serve as root causes of hives (urticaria), particularly in (CSU), where identifiable etiologies are found in up to 20-30% of cases, often involving systemic infections or autoimmune processes. These conditions trigger activation through immune dysregulation, leading to persistent wheal formation and . In children, infections account for approximately 20-30% of urticaria cases, with many acute episodes linked to infectious triggers that may progress to chronic forms. Infections represent a significant category of underlying causes, encompassing viral, bacterial, and parasitic agents that provoke urticaria via direct immune stimulation or inflammatory responses. Viral infections, such as hepatitis B and C, Epstein-Barr virus (EBV), and more recently COVID-19, have been associated with both acute and chronic urticaria, potentially through viral-induced cytokine release or immune complex formation. Bacterial infections, including streptococcal species and Helicobacter pylori, are implicated in up to 10-20% of chronic cases in adults, with H. pylori linked to CSU through gastric inflammation and possible molecular mimicry affecting skin mast cells. Parasitic infections, such as those caused by helminths (e.g., fasciolosis) or protozoa (e.g., Blastocystis hominis), show higher seropositivity in CSU patients compared to controls, contributing to chronic symptoms via eosinophil-mediated mechanisms. Eradication of H. pylori with antibiotics resolves urticaria in 40-50% of associated cases, as demonstrated in meta-analyses comparing treatment success rates to controls. Autoimmune diseases are strongly linked to chronic urticaria, with associations observed in 30-50% of adult cases, often involving autoantibodies that cross-react with skin receptors. Thyroid disorders, particularly , coexist in up to 10-20% of CSU patients, potentially due to shared autoimmune pathways like anti-thyroid antibodies correlating with anti-FcεRI autoantibodies. (RA) and (SLE) are also prevalent, with RA found in about 2% of female CSU patients—significantly higher than in the general population—and SLE showing elevated odds ratios in large cohort studies. Urticarial vasculitis emerges as a distinct autoimmune entity, characterized by leukocytoclastic vasculitis on , lasting longer than 24 hours per lesion, and often associated with hypocomplementemia in diseases. Other systemic conditions occasionally underlie chronic urticaria, though less commonly. Malignancies, such as lymphomas (e.g., or ), are rare triggers in less than 1% of cases but warrant investigation in refractory or atypical presentations, as paraneoplastic urticaria may resolve with tumor treatment. Hormonal imbalances, including those from autoimmunity or other endocrine disruptions, can exacerbate urticaria through altered immune regulation, though direct causality remains under study. (HAE), while distinct from true urticaria due to bradykinin mediation rather than , can mimic hives with non-pruritic swelling, necessitating differentiation via levels to avoid misdiagnosis.

Pathophysiology

Mast Cell Activation and Histamine Release

Mast cells and serve as the primary effector cells in the of hives, residing in the skin and mucosal tissues where they respond to various stimuli by undergoing and releasing preformed mediators such as . These cells are strategically located near vessels and endings, enabling rapid mediation of local inflammatory responses upon activation. In urticaria, activation is the initiating event that leads to the characteristic wheals and itching, with basophils contributing through recruitment and additional mediator release in chronic forms. Histamine, the principal mediator released from these granules, exerts its effects by binding to specific receptors on endothelial cells, smooth muscle, and sensory nerves. Binding to H1 receptors on post-capillary venules induces vasodilation and increases vascular permeability, resulting in plasma extravasation and the formation of edematous wheals; it also stimulates H1 receptors on C-fiber nerve endings to provoke pruritus. H2 receptors may contribute to further vasodilation in the skin, while H4 receptors, expressed on immune cells and keratinocytes, play a role in enhancing itch and inflammation. Following degranulation, histamine levels in the skin and venous plasma typically peak within 1-3 minutes of activation, rapidly declining to baseline within 4-13 minutes due to rapid metabolism by histaminases and uptake mechanisms. Activation of mast cells and in occurs through diverse triggers, including immunological and non-immunological pathways. In allergic urticaria, allergens bind to IgE antibodies on the high-affinity FcεRI receptors, leading to receptor cross-linking and subsequent . Direct degranulators, such as opioids like , bypass IgE and provoke release via G-protein-coupled receptor signaling on mast cell membranes. In neurogenic urticaria, neuropeptides such as activate mast cells through MRGPRX2 receptors, contributing to stress- or emotion-induced flares. Tryptase, another granule-associated released alongside , serves as a reliable serum marker for activation in urticaria, with levels peaking within 1-4 hours post-degranulation and returning to baseline within 24 hours. Elevated during acute episodes helps confirm involvement and distinguish it from other causes of similar symptoms, though baseline levels remain normal in most non-mastocytosis cases of hives.

Inflammatory Mediators and Pathways

In addition to , various non-histamine mediators play crucial roles in amplifying , formation, and inflammatory cell recruitment in urticaria. Leukotrienes, such as LTB4 and LTC4, are released from activated mast cells and contribute to the by promoting through increased vascular leakage and recruiting and neutrophils to the site of . For instance, LTC4 directly induces urticaria-like skin reactions when injected intradermally, underscoring its vasoactive properties. Similarly, prostaglandins like PGD2 enhance and exacerbate wheal formation, while , particularly in cases overlapping with , sustains deeper tissue swelling by stimulating endothelial cell contraction and fluid extravasation, often independent of histamine pathways. Cytokines further sustain the inflammatory cascade in urticaria, particularly in allergic and chronic forms. In allergic urticaria, IL-4, IL-5, and IL-13 drive Th2 immune skewing, promoting IgE production, activation, and sensitization, which prolongs the wheal-and-flare response. In , TNF-alpha is upregulated in lesional skin, fostering persistent inflammation by enhancing adhesion molecule expression and leukocyte infiltration. These cytokines, often derived from s and other immune cells following initial , amplify the overall response. Recent studies (as of 2024) emphasize additional intracellular pathways, including BTK and SYK signaling, in sustaining activation in chronic forms. Platelet-activating factor (PAF), a potent mediator, contributes significantly to the late-phase reactions in urticaria, inducing prolonged release, and , and that can persist for several hours. Elevated PAF levels correlate with disease severity and resistance in chronic cases. In chronic urticaria, signaling pathways such as JAK-STAT, particularly the IL-6/JAK/ axis, mediate cytokine-driven inflammation, leading to sustained activation and immune cell recruitment in lesional skin.

Autoimmune and Infectious Mechanisms

In autoimmune urticaria, a subset of chronic spontaneous urticaria (CSU), circulating autoantibodies such as IgG or IgM target the high-affinity IgE receptor (FcεRI) on mast cells or basophils, or directly bind to IgE, leading to inappropriate mast cell activation and histamine release independent of allergen exposure. This mechanism underlies approximately 30-50% of CSU cases, distinguishing it from type I allergic responses. Detection of anti-FcεRI antibodies occurs in about 40% of patients with chronic urticaria, often correlating with more severe and refractory disease. Infectious processes contribute to urticaria pathogenesis through mechanisms like molecular mimicry, where microbial antigens structurally resemble self-proteins, prompting cross-reactive immune responses that trigger mast cell degranulation. Persistent immune activation following infection can sustain urticaria, particularly in chronic forms, by maintaining inflammatory signaling even after pathogen clearance. Post-viral urticaria, commonly associated with respiratory or gastrointestinal viruses, typically resolves spontaneously within a few weeks. Complement system involvement amplifies urticaria in autoimmune contexts, where immune complexes activate the classical pathway to generate C5a anaphylatoxin, which binds to receptors and enhances release. In hereditary forms linked to complement dysregulation, such as certain variants with urticarial features, C5a contributes to episodic swelling and wheal formation. Additionally, innate immunity pathways, including toll-like receptors (TLRs), recognize bacterial components like lipopolysaccharides, initiating proinflammatory cascades that can precipitate urticaria in susceptible individuals during infections.

Diagnosis

Clinical History and Examination

The clinical history is the cornerstone of evaluating patients presenting with (urticaria), focusing on the temporal pattern, potential triggers, and associated features to guide . Key elements include the onset of symptoms, which is typically sudden and occurs over minutes to hours, with individual wheals resolving within 24 hours while new lesions may appear in successive crops. Duration helps distinguish acute urticaria (lasting less than 6 weeks) from chronic forms (persisting beyond 6 weeks), though a detailed timeline is essential as acute episodes often resolve spontaneously. Potential triggers should be explored systematically, such as recent exposures to foods (e.g., , nuts), medications (e.g., NSAIDs, antibiotics), infections, physical factors (e.g., pressure, ), or stress, as these are commonly implicated in acute cases. Family history is pertinent, particularly for hereditary conditions like , and associated symptoms such as intense pruritus, fever, joint pain (), or gastrointestinal upset may point to underlying systemic involvement. In chronic urticaria, a thorough history often reveals no identifiable trigger in 80% to 90% of cases, underscoring the idiopathic nature of . For acute urticaria, the history frequently identifies a cause in approximately 50% of episodes, such as allergens or infections, facilitating targeted management. Red flags in the history include systemic symptoms like persistent fever, arthralgia, or weight loss, which may suggest urticarial vasculitis, infection, or other underlying conditions requiring further evaluation beyond routine hives. Physical examination begins with a comprehensive inspection of the skin to characterize wheal morphology, noting their raised, blanching, edematous appearance with surrounding , varying in size from millimeters to centimeters, and shapes that can be round, annular, or . The transient nature of lesions necessitates assessing their extent and distribution, often across the trunk, limbs, or face, while documenting any accompanying , which presents as non-pitting swelling in deeper tissues like the , eyelids, or extremities and affects up to 40% of chronic cases. Dermographism is evaluated by gently stroking the skin with a blunt instrument to elicit linear wheals, a finding present in about 4% to 5% of the general population but more indicative of physical urticaria when symptomatic. and a search for systemic signs, such as tachycardia or mucosal involvement, are critical to identify complications like or .

Diagnostic Testing

Diagnostic testing for hives, or urticaria, is typically reserved for cases where the clinical history and examination suggest the need to identify underlying causes or rule out mimics, particularly in (CSU) lasting more than six weeks. Guidelines recommend a targeted approach to avoid unnecessary investigations, focusing on routine tests to assess for , , or associated conditions. Routine laboratory evaluations often include a (CBC) to detect eosinophilia, which may indicate allergic or parasitic involvement, and (ESR) or (CRP) to evaluate for or . , including assessment for anti-thyroid antibodies such as anti-thyroid peroxidase (anti-TPO), are recommended due to their association with autoimmune in CSU, with positivity observed in approximately 15-20% of chronic cases. These tests help identify comorbidities like , though their direct causal role remains unclear. Allergy testing is not routinely performed but may be indicated if the history points to specific triggers. Skin prick tests or serum-specific IgE measurements can evaluate for to allergens like foods or medications in acute urticaria. For suspected , the autologous serum skin test (ASST) involves of the patient's serum; a positive result, defined as a wheal at least 1.5 mm larger than the saline control, suggests auto-reactivity against IgE or its receptor. Specialized tests are employed based on clinical suspicion. Skin biopsy is rarely required, in less than 5% of cases, but is essential when urticarial vasculitis is suspected, such as with lesions persisting beyond 24 hours or accompanied by ; typically reveals leukocytoclastic with fibrinoid and perivascular infiltrates. For chronic inducible urticaria, provocation or challenge tests confirm physical triggers: the ice cube test (applying ice for 5 minutes) diagnoses if hives develop upon rewarming, while a dermographism test uses gentle skin stroking with a blunt instrument to elicit linear wheals. These tests should be conducted under medical supervision to monitor for severe reactions. For recurrent angioedema without urticaria, (HAE) should be ruled out by measuring serum C4 levels (persistently low), C1 esterase inhibitor (C1-INH) antigenic level, and functional activity.

Differential Diagnosis

The differential diagnosis of (urticaria) is essential to distinguish transient, pruritic wheals from other dermatologic and systemic conditions that may mimic them, preventing misdiagnosis and ensuring appropriate management. Key differentials include disorders, autoimmune blistering diseases, and contact reactions, each characterized by distinct morphology and duration. Mastocytosis presents with persistent, hyperpigmented macular or papular lesions that urticate upon mechanical stroking (), unlike the fleeting wheals of urticaria that resolve within 24 hours. features dull red, target-like lesions predominantly on the extremities, often accompanied by mucosal erosions and fever, contrasting with the migratory, non-targetoid pruritic hives. manifests as intensely pruritic urticarial plaques that evolve into tense bullae over days, differing from urticaria by the presence of subepidermal blisters and infiltration on . typically shows fixed, eczematous patches with vesicles in areas of exposure, spreading with gravity but without the central and evanescent nature of hives. Vascular mimics such as involve wheals lasting longer than 24 hours, often painful with residual or upon resolution, and confirms leukocytoclastic vasculitis in 5-10% of suspected chronic urticaria cases. causes nonpruritic, deep subcutaneous swellings without wheals, frequently involving the face, extremities, or abdomen with potential for severe pain and life-threatening airway compromise. without accompanying hives occurs in approximately 10% of patients, and in such cases, should be ruled out through screening for complement deficiencies (e.g., low C4, C1-INH). Other conditions to consider include drug eruptions, which produce symmetrical maculopapular rashes persisting for days and potentially desquamating, linked to recent exposure in less than 10% of urticaria presentations. Insect bites result in localized urticarial papules (2-10 mm) with a central punctum, resolving in 5-10 days and tied to a clear history of exposure. Psychogenic itching lacks visible wheals and is a , often associated with psychological stressors without objective dermatologic findings. In toddlers and young children, small welts on the face are commonly caused by hives (urticaria), which present as raised, red, itchy welts. In young children, the most frequent triggers include minor viral infections, allergic reactions (e.g., to foods, medications, or insect bites/stings), or unknown causes. Other possible causes that may mimic this presentation include insect bites, contact with irritants, or physical triggers. These are not specific diagnoses; consultation with a pediatrician for evaluation is recommended, especially if accompanied by swelling, breathing issues, or persistence.

Treatment and Management

Acute and First-Line Interventions

The first-line treatment for acute urticaria, commonly known as hives, involves second-generation H1 antihistamines such as and loratadine, which effectively block to alleviate itching, swelling, and wheal formation. These agents are preferred due to their nonsedating properties and rapid onset, typically providing symptom relief within hours of administration at standard doses (e.g., 10 mg daily for in adults). In the majority of cases, second-generation H1 antihistamines alone resolve acute episodes by targeting the histamine-mediated response central to urticaria . For cases where symptoms persist despite standard dosing, up-dosing second-generation H1 s up to four times the recommended dose (e.g., up to 40 mg daily) is a common and safe escalation strategy to enhance symptom control without significant sedation. In refractory acute urticaria, adding an H2 such as famotidine (20 mg twice daily) to H1 blockade can further improve resolution rates by addressing residual activity at different receptor sites. This combination has demonstrated superior efficacy over H1 monotherapy in acute settings. For severe acute flares with extensive wheals, , or significant discomfort, short-term oral corticosteroids like are recommended as adjunctive therapy, typically in bursts of 20-40 mg daily for 3-5 days to rapidly suppress inflammation. Such regimens provide quick relief but must be limited to avoid adverse effects associated with prolonged use, including , , and increased infection risk. When acute urticaria overlaps with anaphylaxis—characterized by systemic symptoms like or airway compromise—intramuscular epinephrine (0.3-0.5 mg of 1:1000 solution) is the immediate intervention of choice to reverse life-threatening effects, followed by antihistamines and corticosteroids. This approach ensures prompt stabilization in emergent scenarios.

Chronic and Advanced Therapies

For patients with (CSU) that remains uncontrolled despite standard therapy, , an anti-IgE , serves as a key biologic agent. The U.S. (FDA) approved for CSU in adults and adolescents aged 12 years and older in 2014, with recommended subcutaneous dosing of 150 mg or 300 mg every 4 weeks based on clinical response. Clinical trials, such as the ASTERIA II study, demonstrated that 300 mg every 4 weeks significantly reduced itch severity scores and weekly hive counts compared to placebo, achieving complete response rates of up to 36% and substantial improvement in 60-80% of patients by week 12. According to the European Academy of Allergy and Clinical Immunology (EAACI) guidelines updated in the 2020s, elicits a response in approximately 73% of CSU cases, often within 4-12 weeks, though some patients may require up to 6 months for full effect. Other advanced therapies target specific inflammatory pathways in refractory CSU. Cyclosporine, an immunosuppressant, is recommended at doses of 3-5 mg/kg per day, with a meta-analysis showing it induces remission or significant symptom reduction in about 50% of patients unresponsive to antihistamines and omalizumab. Due to risks including nephrotoxicity, renal function must be monitored regularly, with trough levels kept below 150 ng/mL to minimize adverse effects. Leukotriene receptor antagonists, such as montelukast at 10 mg daily, provide modest add-on benefits by inhibiting leukotriene-mediated inflammation, with systematic reviews indicating improvements in urticaria activity scores and quality of life in 40-60% of cases when combined with antihistamines. Dupilumab, a monoclonal antibody inhibiting IL-4 and IL-13 signaling, has shown promise in phase 3 trials (LIBERTY-CUPOLA I and II) for omalizumab-refractory CSU, reducing weekly itch and hive scores by 45-50% versus placebo after 24 weeks, leading to its FDA approval in April 2025 as a targeted therapy for uncontrolled CSU. In chronic inducible urticaria, specialized therapies address trigger-specific mechanisms. For , narrowband ultraviolet B (NB-UVB) phototherapy is an effective prophylactic option, with protocols involving gradual dose escalation over 20-30 sessions inducing tolerance to sunlight in 70-80% of patients by desensitizing photoallergic pathways. For pressure urticaria, topical cream (0.025-0.075%) applied to affected areas can alleviate symptoms through transient receptor potential vanilloid 1 () desensitization, providing relief in refractory cases as an adjunct to systemic treatments, though evidence is primarily from small observational studies.

Supportive and Preventive Strategies

Supportive and preventive strategies for hives (urticaria) focus on identifying and mitigating triggers to reduce flare frequency and severity, alongside measures to alleviate symptoms and enhance patient well-being. Trigger avoidance is a cornerstone, particularly for inducible forms such as cold, solar, or cholinergic urticaria, where exposure to specific stimuli like temperature changes, sunlight, or physical exertion can provoke wheals. Patients are advised to maintain detailed diet logs to pinpoint food sensitivities, such as pseudoallergens in additives, tomatoes, or histamine-rich items, which may exacerbate symptoms in susceptible individuals. For cold urticaria, wearing protective clothing like gloves, scarves, and layered garments minimizes skin exposure to low temperatures, while sun-protective clothing with ultraviolet protection factor (UPF) is recommended for solar urticaria to limit UV-induced reactions. Stress reduction techniques, including cognitive behavioral therapy (CBT) and relaxation methods like deep breathing or meditation, are beneficial for cholinergic urticaria, as psychological stress can trigger flares by influencing neuro-immune pathways. In inducible urticaria, which accounts for approximately 20% of chronic cases, rigorous trigger avoidance can effectively control or resolve symptoms in many patients, though complete elimination may be challenging. Supportive care emphasizes non-invasive interventions to soothe irritated and prevent secondary . Applying cool compresses, such as a washcloth or wrapped in cloth, for 10-15 minutes several times daily can constrict blood vessels and reduce itching and swelling. Colloidal baths, prepared by adding finely ground to lukewarm water and soaking for 15-20 minutes, provide relief by forming a protective barrier on the . Opting for loose-fitting, smooth clothing avoids friction and pressure that could worsen wheals, while steering clear of tight, rough, or fabrics is advised. For anticipated trigger exposure, premedication with a second-generation (e.g., 10 mg taken 2-6 hours prior) can prophylactically block release in cases like NSAID-associated urticaria. In infants and children, supportive and preventive strategies include avoiding triggers, using cool compresses for relief, and non-drowsy antihistamines safe from 6 months of age; most cases resolve spontaneously, but infants under 6 months with hives may require specialist review. Patient education empowers individuals to monitor their condition and respond appropriately, improving . Mobile applications like CRUSE (Chronic Urticaria Self-Evaluation) enable daily tracking of flare symptoms, impacts, and treatment responses, facilitating better trigger identification and communication with healthcare providers. Education on emergency signs is crucial: seek immediate medical attention if hives are accompanied by throat swelling, difficulty breathing, wheezing, or dizziness, as these may signal requiring epinephrine. education, including CBT, has been shown to alleviate symptoms in chronic urticaria by addressing associated anxiety and improving coping mechanisms.

Prognosis and Complications

Outcomes for Acute and Chronic Forms

Acute urticaria, defined as lasting less than , generally has an excellent with most cases resolving spontaneously within one week, though individual wheals typically clear within 24 hours while new ones may appear. This is especially true in babies and children, where most cases resolve on their own without treatment. The recurrence risk is approximately 25% after initial resolution, increasing only if an identifiable trigger such as or persists. Medical attention should be sought for recurrent or persistent hives lasting more than six weeks, or immediately if signs of anaphylaxis appear (e.g., breathing difficulty, swelling of face/tongue, pale/floppy appearance in infants). In contrast, chronic urticaria, persisting beyond six weeks, follows a more variable course with approximately 50% of patients achieving remission within one year and an overall rate of about 80% over several years. Around 20% of cases continue for more than five years, though improves significantly if a trigger is identified and eliminated. Key prognostic factors include younger age at onset and the presence of , both associated with prolonged disease duration, whereas absence of correlates with shorter courses. Female sex is linked to worse outcomes in chronic forms, potentially due to hormonal influences. Autoimmune subtypes of chronic urticaria tend to last longer than non-autoimmune or inducible forms, with remission rates as low as 16% within three years for autoimmune subtypes compared to 48% for idiopathic cases.

Epidemiology

Prevalence and Incidence

Urticaria, commonly known as hives, has a lifetime of approximately 15-25% worldwide, meaning that up to one in four individuals may experience it at some point in their lives. Acute urticaria, which lasts less than six weeks, accounts for the vast majority of cases, comprising 80-90% of all episodes, while chronic forms persist beyond this duration and are less common. The condition's high lifetime occurrence underscores its status as one of the most frequent skin disorders globally. Annual incidence rates for new cases of urticaria are estimated at 1-2% of the population, with acute urticaria showing higher rates among children and adolescents, often triggered by infections or allergens, whereas chronic urticaria tends to onset more frequently in adults. In 2017, the global incidence reached about 160 million new cases; by 2021, this had increased to approximately 117 million incident cases and 66 million prevalent cases, according to the Global Burden of Disease Study, reflecting a steady increase over time due to factors like environmental exposures and population growth. For chronic spontaneous urticaria specifically, the point prevalence is 0.5-1% in the general population, with women affected at approximately twice the rate of men in adulthood (female:male ratio of 2:1). Geographic and environmental variations influence urticaria's occurrence, with higher rates observed in urban areas attributed to increased exposure to allergens, pollutants, and irritants. Following the in the early , there was a notable spike in acute urticaria cases, with urticaria comprising up to 14.8% of reported cutaneous manifestations in patients, potentially linked to viral immune responses. These trends highlight the condition's responsiveness to external triggers and its evolving burden in modern settings.

Demographic Patterns and Risk Factors

Hives, or urticaria, exhibit distinct demographic patterns, with acute forms predominantly affecting children under 10 years of age, where approximately 15% experience at least one episode. In contrast, chronic urticaria tends to peak in adulthood, particularly between 20 and 40 years. Regarding sex differences, chronic urticaria disproportionately impacts females, with a female-to-male ratio of about 2:1, attributed in part to hormonal influences. This disparity is less pronounced in acute cases but remains notable across demographics. Geographically, urticaria prevalence shows regional variations, with higher rates reported in and Central and compared to other areas, potentially linked to differences in environmental exposures and healthcare reporting. Ethnic patterns indicate elevated occurrence among Black Americans and certain other non-white groups relative to white populations. In Western countries, where atopic conditions are more prevalent, this predisposition contributes to increased urticaria risk, with (including , , and ) conferring odds ratios of 1.87 to 2.94 for chronic forms. Key risk factors for chronic urticaria include , present in 40-50% of cases, which heightens susceptibility through shared allergic mechanisms. Modifiable risks encompass , associated with higher and (odds ratio approximately 1.5-2 in population studies), , which elevates risk via inflammatory pathways, and NSAID use, a common trigger in susceptible individuals. Genetic factors, particularly in autoimmune subtypes, involve HLA class II associations such as HLA-DRB1 and HLA-DQA1 alleles, increasing s up to 1.86 for disease development. Additionally, women may experience worsening of symptoms post-menopause due to hormonal shifts exacerbating autoimmune responses.

History

Early Descriptions and Recognition

The earliest known descriptions of hives, or urticaria, date back to ancient civilizations, where the condition was recognized for its characteristic itchy, transient welts resembling nettle stings. In ancient Greece, Hippocrates (c. 460–377 BCE) provided one of the first detailed accounts in the Corpus Hippocraticum, terming the affliction "knidosis" after the Greek word knidō for nettle, noting its sudden onset of elevated, pruritic lesions often triggered by external irritants like insect bites or environmental factors. This observation highlighted the rash's fleeting nature, distinguishing it from more persistent skin disorders of the era. Similarly, ancient Chinese texts, such as the Huang Di Nei Jing (Yellow Emperor's Inner Classic, c. 200 BCE), described a "wind-induced rash" (feng yin zheng), attributing it to imbalances in bodily fluids and winds, which caused hidden, eruptive itches. By the Renaissance period, European physicians began drawing explicit parallels between the human rash and the stinging effects of the nettle plant (Urtica dioica), a similarity first notably observed in medical writings from the 1500s, such as those by Paracelsus, who linked the condition to humoral imbalances producing nettle-like eruptions. The English term "hives," denoting a sudden, explosive outbreak of the disease, emerged in Scottish medical parlance around the late 15th to 17th centuries, derived from a dialect word implying a rapid "heaving" or rush of affliction, often applied to eruptive childhood skin conditions. This vernacular name persisted alongside more formal Latin descriptors, reflecting the condition's dramatic, swarm-like appearance. In the , systematic classification advanced with the Scottish physician William Cullen, who in 1769 formally introduced the term "urticaria" in his Synopsis Nosologiae Methodicae, deriving it from the Latin urtica (nettle) to capture the rash's burning, wheal-forming quality. The brought cellular insights, as identified mast cells in 1878 during his doctoral thesis, describing their granular, metachromatic properties in connective tissues—cells later recognized as central to urticaria's through release. Around the same time, Heinrich Quincke detailed acute circumscribed in 1882, coining "Quincke's edema" (now ), which often co-occurs with urticaria and marked early differentiation of deeper swelling from superficial hives. By the early 1900s, clinicians distinguished acute urticaria (resolving within weeks) from chronic forms (persisting beyond six weeks), with Ferdinand von Hebra's 19th-century dermatological works laying groundwork by categorizing persistent "nettle rashes" separately from transient episodes. Food triggers gained recognition in the early amid emerging science; for instance, clinicians such as Oscar M. Schloss in 1912 used scratch tests to diagnose food allergies causing symptoms like recurrent hives, building on earlier observations of links to foods such as via elimination diets. These observations shifted understanding from vague humoral theories to specific etiological factors.

Key Developments in Understanding and Treatment

In the early , the discovery of as a key mediator in allergic reactions marked a foundational advancement in understanding hives, also known as urticaria. In 1910, Sir Henry Dale and his colleagues at the Wellcome Laboratories isolated from and demonstrated its physiological effects, including and increased , which directly contribute to the wheal-and-flare response characteristic of urticaria. This breakthrough shifted perceptions from hives as merely symptomatic to a histamine-driven process, paving the way for targeted therapies. The mid-20th century saw the introduction of , revolutionizing treatment for urticaria. Developed in the 1930s, the first H1-antihistamines, such as phenbenzamine, emerged as effective blockers of , with clinical availability expanding in the 1940s for allergic conditions including . A landmark example was diphenhydramine (), approved by the FDA in 1946 as the first prescription in the United States, providing symptomatic relief by inhibiting histamine-induced itching and swelling. By the late 1940s, these agents had become standard for managing acute and chronic urticaria, though first-generation options often caused sedation. The brought insights into autoimmune mechanisms in chronic urticaria, alongside adaptations of immunosuppressants. Researchers identified functional autoantibodies, including IgG anti-FcεRI antibodies, in subsets of patients with chronic idiopathic urticaria, where these antibodies trigger degranulation independently of IgE. Concurrently, cyclosporine, originally approved in 1983 for to prevent rejection by inhibiting T-cell activation, was adapted for refractory chronic urticaria in the late , showing efficacy in reducing symptoms through at low doses. The approval of in 2003 for moderate-to-severe allergic represented a biologic milestone, with its extension to chronic idiopathic urticaria in 2014 by the FDA for patients unresponsive to antihistamines. This neutralizes free IgE and downregulates FcεRI expression on mast cells and , addressing autoimmune and IgE-mediated subsets of urticaria. International guidelines evolved accordingly, with the 2009 EAACI/GA²LEN/EDF/WAO standards recommending up-dosing of second-generation H1-antihistamines as first-line , followed by add-on options like H2-antihistamines or cyclosporine. Updates in the 2020s, including the 2022 EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline, incorporated biologics like as second-line treatment and explored emerging agents such as for refractory cases. Post-2020, studies highlighted associations between vaccines and urticaria flares or new-onset cases, particularly with mRNA vaccines like Pfizer-BioNTech and . Large cohort analyses reported a 3-4-fold increased risk of hives within 90 days of , though most cases were mild and self-limited, informing safety in urticaria patients. These findings prompted guideline revisions to emphasize monitoring and in at-risk individuals.

Research Directions

Current Studies on Mechanisms

Recent genome-wide association studies (GWAS) have identified several genetic loci associated with susceptibility to chronic urticaria, highlighting its overlap with autoimmune disorders. A 2023 meta-analysis of GWAS data revealed six significant risk loci associated with chronic urticaria, including variants near genes such as FCER1A and HLA-DQA1, implicating biology and immune regulation. Additionally, (HLA) alleles, particularly HLA-B44 and HLA-DRB1*04, have been implicated as susceptibility markers in chronic forms, with carriage of HLA-B44 correlating with increased disease risk in diverse populations. These findings underscore a polygenic basis for chronic urticaria, distinct from atopic conditions, and suggest shared genetic pathways with diseases like and . Investigations into the gut microbiome have linked dysbiosis to the pathogenesis of chronic urticaria, with altered bacterial compositions potentially driving immune dysregulation. Studies from 2024 demonstrate reduced microbial diversity in patients with chronic spontaneous urticaria (CSU), characterized by decreased abundance of short-chain fatty acid-producing bacteria like Faecalibacterium and increased Proteobacteria, which may promote systemic inflammation via leaky gut mechanisms. Helicobacter pylori infection has been associated with urticaria flares, as evidenced by Mendelian randomization analyses showing a bidirectional causal relationship between H. pylori presence and allergic skin conditions, including urticaria, possibly through toxin-induced mast cell degranulation. Furthermore, post-antibiotic microbiome disruptions, such as those following broad-spectrum therapy, have been observed to trigger urticarial exacerbations by diminishing regulatory T-cell populations and elevating lipopolysaccharide levels, thereby enhancing mast cell responsiveness. Neuro-immune interactions play a key role in stress-induced urticaria, mediated by neuropeptides that bridge psychological stressors and activation. Elevated serum levels of (SP) have been documented in CSU patients, correlating with symptom severity and promoting release from mast cells via neurokinin-1 receptors. (CGRP), often co-released with SP from sensory nerves, exacerbates wheal formation in stress models by amplifying and production. Recent 2024 research confirms that activates these pathways, leading to HPA axis dysregulation and subsequent urticaria flares, independent of IgE-mediated mechanisms. Studies from 2023 to 2025 have advanced understanding of autoinflammatory subtypes of urticaria through examination of the inflammasome, a multiprotein complex central to innate immunity. In cryopyrin-associated periodic syndromes (CAPS), gain-of-function mutations in lead to excessive IL-1β production, manifesting as urticarial rashes alongside fever and ; recent analyses highlight 's role in non-hereditary autoinflammatory urticaria, where inflammasome hyperactivation drives mast cell-independent inflammation. Similarly, in —a rare acquired autoinflammatory disorder featuring chronic urticaria—2025 investigations implicate dysregulation alongside , with IL-1β blockade proving effective in mitigating symptoms. Single-cell RNA sequencing (scRNA-seq) has further revealed mast cell heterogeneity in urticaria, identifying distinct subpopulations with varying expression of activation markers like FCER1A and proinflammatory genes such as TPSAB1. A 2025 study using scRNA-seq on lesional from CSU patients uncovered two major mast cell clusters: one enriched in neurogenic inflammatory pathways (e.g., TAC1 for SP) and another in adaptive immune responses, explaining phenotypic variability across patients. These insights from scRNA-seq emphasize tissue-specific mast cell plasticity, informing targeted mechanistic research.

Emerging Treatments and Clinical Trials

Bruton tyrosine kinase (BTK) inhibitors represent a promising class of oral therapies for (CSU), targeting and activation. Rilzabrutinib, developed by , demonstrated significant efficacy in the phase 2 trial (RILECSU), meeting its primary endpoint with a reduction in weekly severity score (ISS7) and weekly urticaria activity score (UAS7) compared to , achieving approximately 50-60% improvement in UAS7 scores by week 12 in antihistamine-refractory patients, with phase 3 trials ongoing. Similarly, remibrutinib () completed phase 3 trials (REMIX-1 and REMIX-2), showing rapid symptom control with over 50% of patients reaching UAS7=0 by week 52 and a favorable safety profile, including low rates of adverse events like petechiae (3.8% vs. 0.3% ), which received FDA approval (as Rhapsido) on September 30, 2025, providing an oral option for adults with CSU uncontrolled by H1-antihistamines. Interim analyses from these studies indicate that BTK inhibitors elicit responses in 60-70% of non-responders, offering a viable option for refractory CSU. Agents targeting the IL-4/IL-13 pathway, such as (/Regeneron), have shown substantial benefits in phase 3 trials (LIBERTY-CUPID A/B) for patients uncontrolled on H1-antihistamines, with 30-51% achieving complete remission (UAS7=0) at week 24 and significant reductions in itch and hive severity versus . This led to FDA approval in April 2025 as the first new biologic for CSU in over a decade, particularly effective in omalizumab-naïve cases. In contrast, anti-IL-5 therapies like remain in exploratory phases, with small studies suggesting modest activity in CSU but no phase 3 advancement as of 2025. Studies on mRNA -induced urticaria, including post-COVID-19 and experimental vaccine trials, have identified delayed-onset chronic urticaria in 6-7% of recipients, often resolving within months with standard protocols and monitoring for recurrence upon revaccination. Ongoing research emphasizes early intervention with second-generation H1- and avoidance of triggers to achieve resolution rates exceeding 80% without long-term sequelae. Siglec-8 inhibitors, such as antolimab, are under investigation in phase 2 trials for CSU, aiming to inhibit degranulation and activity; preliminary data from 2025 EAACI presentations highlight potential in refractory cases, though full results are pending. Lirentelimab, another Siglec-8 , showed clinical activity in an open-label phase 2a study but failed to meet primary endpoints in phase 2b, prompting refined dosing strategies in ongoing evaluations.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.